Centene Corp. (CNC) Intrinsic Value & DCF Valuation
Medical - Healthcare Plans · NYSE
Current Price
$65.02
Intrinsic Value
$123.32
+47.3% margin of safety
What Is Centene Corp.'s Intrinsic Value?
As of 2026-08-21, the base-case DCF model estimates the intrinsic value of Centene Corp. (CNC) at $123.32 per share, compared with a market price of $65.02, a margin of safety of +47.3%. The base case assumes 3.4% annual free cash flow growth and a 10.0% discount rate.
Across the sensitivity grid the estimate spans $83.62 to $176.39. Intrinsic value is an estimate built on assumptions, not a fact. A higher discount rate or slower growth pushes the estimate down, while stronger cash flow growth lifts it.
How the DCF works · Recalculate with your own assumptions · What is intrinsic value?
Is Centene Corp. (CNC) Undervalued?
At the current price of $65.02, CNC trades well below the base-case intrinsic value estimate, a margin of safety above 30%. By this model the stock looks undervalued, but verify the growth assumptions match your own view before acting.
COMPETITIVE MOAT
↑Government Contract Dominance
Centene's deep experience and scale in managing government-sponsored health plans (Medicaid, Medicare) create significant barriers to entry for new competitors. This expertise is difficult to replicate quickly.
↑Extensive Provider Network
A large and established network of healthcare providers is crucial for managing costs and ensuring member access. Centene's scale allows for favorable contract negotiations and broad geographic coverage.
↑Data & Scale Advantage
Centene's vast member base generates substantial data, enabling sophisticated risk management, cost optimization, and personalized member services. This scale provides a competitive edge in efficiency.
INVESTMENT RISKS
↓CFO Transition Uncertainty
The planned transition of the Chief Financial Officer role introduces a period of leadership change. While a successor is named, the integration and continuity of financial strategy could face challenges.
↓Execution Risk in Growth Strategies
Centene's growth often relies on acquisitions and expanding into new markets. Successful integration and realization of synergies from these initiatives are critical and carry inherent execution risks.
↓Operational Complexity & Cost Management
Managing a large, diverse membership across multiple government programs is operationally complex. Inefficient cost management or unexpected increases in healthcare utilization can significantly impact financial performance.
Base case
CNC base case valuation
Intrinsic Value
$123.32
Margin of safety
+47.3%
Expected annual return
+13.7%
Base case assumptions: 3.4% annual growth, 10.0% discount rate, 3.58x exit multiple, 5 year projection. Data as of 2026-08-21.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the CNC valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Centene Corp. respond.
Open DCF Calculator for CNCCompany Overview
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Financial Metrics — CNC Stock Valuation Data
Revenue/Share (TTM)
$392.32
FCF/Share (TTM)
$18.16
ROIC (TTM)
-12.9%
ROE (TTM)
-24.0%
P/FCF
3.6x
EV/EBITDA
-8.3x
FCF Yield
27.92%
Debt/Equity
0.71x
Based on trailing twelve-month data, CNC shows a free cash flow per share of $18.16 and a ROIC of -12.9%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 3.6x and FCF yield of 27.92% are important context metrics when evaluating CNC's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of CNC?
Centene Corp. currently generates $18.16 in free cash flow per share. At the current price of $65.02, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is CNC undervalued?
CNC trades at a P/FCF ratio of 3.6x with a free cash flow yield of 27.92%. A low P/FCF means investors are paying less per dollar of free cash flow; whether that is cheap depends on the company's growth, cyclicality, and capital intensity. However, whether CNC is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value CNC stock using DCF?
To perform a DCF valuation on Centene Corp.: (1) Start with the trailing free cash flow per share ($18.16) as the base, (2) project future FCF growth over 5-10 years based on Medical - Healthcare Plans industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting CNC's risk profile — with a debt-to-equity of 0.71x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to CNC?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Centene Corp., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Healthcare Plans trends, then discounting those amounts to today's dollars. CNC's ROIC of -12.9% means the company's return on invested capital sits below the level that typically clears its cost of capital.
How does WACC affect CNC stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For CNC, with a debt-to-equity ratio of 0.71x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of -8.3x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See CNC PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value CNC with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-08-21. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.